… Our aim was to assess the efficacy and safety of HIFU in both primary treatment of men with
… advanced prostate cancer as well as salvage treatment of men with recurrent prostate cancer …

… Prostate cancer (PCa) is the most common noncutaneous malignancy and the second leading
cause of cancer … The average survival for patients with castration-resistant prostate cancer …

… prostate cancer, where it emits high-energy alpha-particle radiation that causes severe
DNA damage in nearby cells (Fig. 5B) (Henriksen et al. 2002, Bruland et al. 2006, Parker et al. …

… Our results demonstrate for the first time high efficacy of a PI3Kβ/δ inhibitor in PCa preclinical
models in combination with androgen deprivation. In a PTEN-negative PDX model, it …

… High dose-rate (HDR) brachytherapy as a monotherapy is an accepted … prostate cancer,
but the optimal dose and fractionation schedule remain unknown. We report on the efficacy of a …

… Later, 2 randomised trials were started involving 1453 patients with M1 and M0 prostate
cancer and using a 3 times higher dose of bicalutamide (150 mg/day). M0 patients showed …

… developed to specifically target prostate cancer tissue by use … , may be extended to prostate
cancer therapeutic applications for … and developments in nanomedicines for prostate cancer. …

… are the efficacy and side effects of HIFU in the primary treatment of localised prostate
cancer?” … This work was part of a larger project by the KCE on prostate cancer, entitled “National …

Background The optimal treatment for patients with high-risk prostate cancer (PCa) remains
a debate and selection of patients to receive proper therapy is still an unsettled question. …

… For non-advanced prostate cancer, prostatectomy remains a primary treatment option. … , for
advanced prostate cancer, which is commonly known as castration resistant prostate cancer (…